Pharma procurement is under more pressure than it has seen in decades.
Escalating regulatory mandates, fragile API supply chains, rising quality failures, and record drug shortages are converging—placing procurement at the heart of compliance, continuity, and patient safety. What was once focused on cost and sourcing efficiency is now responsible for traceability, audit readiness, and multi-tier supplier risk control.

This report explores how procurement in Pharmaceuticals & Life Sciences is approaching a critical inflection point—and why Source-to-Pay is fast becoming the operating backbone for quality, compliance, and supply resilience through 2026.

What’s Inside the Report?

• The five macro forcesreshaping pharma procurement through 2026
• Why regulatory tighteningis pushing compliance upstream into sourcing and contracts
• How API dependency and drug shortagesare redefining supplier strategies
• The growing impact of quality failures, recalls, and multi-tier supplier risk
• Why R&D acceleration and CDMO/CRO ecosystemsare increasing procurement complexity

Download the Report

Procurement Horizons – 2026: Pharmaceuticals & Life Sciences Sector

Gain a forward-looking perspective on how procurement will shape compliance, supply resilience, and patient outcomes—and what pharma leaders must do now to stay ahead of regulatory and supply-chain convergence.